ivermectin
fdaapprov
broad
spectrum
antiparasit
agent
gonzalez
canga
et
al
recent
year
along
group
shown
antivir
activ
broad
rang
virus
gotz
et
al
lundberg
et
al
tay
et
al
wagstaff
et
al
vitro
origin
identifi
inhibitor
interact
human
immunodefici
integras
protein
importin
imp
heterodim
respons
nuclear
import
wagstaff
et
al
ivermectin
sinc
confirm
inhibit
nuclear
import
replic
action
ivermectin
report
mastrangelo
et
al
ivermectin
shown
inhibit
nuclear
import
host
eg
kosyna
et
al
van
der
watt
et
al
viral
protein
includ
simian
viru
larg
tumour
antigen
tag
dengu
viru
denv
nonstructur
protein
wagstaff
et
al
importantli
demonstr
limit
infect
rna
virus
denv
tay
et
al
west
nile
viru
yang
et
al
venezuelan
equin
enceph
viru
veev
lundberg
et
al
influenza
gotz
et
al
broad
spectrum
activ
believ
due
relianc
mani
differ
rna
virus
infect
cali
et
al
jan
et
al
ivermectin
similarli
shown
effect
dna
viru
pseudorabi
viru
prv
vitro
vivo
ivermectin
treatment
shown
increas
surviv
prvinfect
mice
lv
et
al
efficaci
observ
ivermectin
zika
viru
zikv
mice
author
acknowledg
studi
limit
justifi
reevalu
ivermectin
antizikv
activ
ketkar
et
al
final
ivermectin
focu
phase
iii
clinic
trial
thailand
denv
infect
singl
daili
oral
dose
observ
safe
result
signific
reduct
serum
level
viral
protein
chang
viremia
clinic
benefit
observ
see
yamasmith
et
al
caus
agent
current
pandem
singl
strand
posit
sens
rna
viru
close
relat
sever
acut
respiratori
syndrom
coronaviru
sarscov
studi
sarscov
protein
reveal
potenti
role
infect
signaldepend
nucleocytoplasm
shut
sarscov
nucleocapsid
protein
rowland
et
al
timani
et
al
wulan
et
al
may
impact
host
cell
divis
hiscox
et
al
wurm
et
al
addit
sarscov
accessori
protein
shown
antagon
antivir
activ
transcript
factor
sequest
rough
ergolgi
membran
frieman
et
al
taken
togeth
report
suggest
ivermectin
nuclear
transport
inhibitori
activ
may
effect
test
antivir
activ
ivermectin
toward
infect
verohslam
cell
isol
moi
h
follow
addit
ivermectin
supernat
cell
pellet
harvest
day
analys
rtpcr
replic
rna
fig
author
would
like
reader
awar
follow
letter
issu
fda
titl
use
ivermectin
intend
anim
treatment
covidat
h
reduct
viral
rna
present
supernat
indic
releas
virion
sampl
treat
ivermectin
compar
vehicl
dmso
similarli
reduct
cellassoci
viral
rna
indic
unreleas
unpackag
virion
observ
ivermectin
treatment
h
effect
increas
reduct
viral
rna
ivermectintr
compar
control
sampl
indic
ivermectin
treatment
result
effect
loss
essenti
viral
materi
h
consist
idea
reduct
viral
rna
observ
h
observ
previous
lundberg
et
al
tay
et
al
wagstaff
et
al
toxic
ivermectin
observ
timepoint
test
either
sampl
well
parallel
test
drug
alon
sampl
determin
effect
ivemectin
cell
infect
treat
serial
dilut
ivermectin
h
post
infect
supernat
cell
pellet
collect
realtim
rtpcr
h
fig
reduct
viral
rna
observ
supernat
cell
pellet
sampl
treat
ivermectin
h
equat
reduct
viral
rna
sampl
toxic
observ
ivermectin
concentr
test
ivermectin
treatment
determin
condit
underlin
fact
assay
inde
specif
detect
rtpcr
experi
repeat
use
primer
specif
viral
rdrp
gene
fig
f
rather
e
gene
nearli
ident
result
observ
releas
supernat
cellassoci
viru
taken
togeth
result
demonstr
ivermectin
antivir
action
clinic
isol
vitro
singl
dose
abl
control
viral
replic
within
h
system
hypothesis
like
inhibit
nuclear
import
viral
protein
fig
shown
rna
virus
tay
et
al
wagstaff
et
al
yang
et
al
confirm
mechan
case
identif
specif
andor
host
compon
impact
see
yang
et
al
import
focu
futur
work
laboratori
ultim
develop
effect
antivir
given
patient
earli
infect
could
help
limit
viral
load
prevent
sever
diseas
progress
limit
personperson
transmiss
benchmark
test
ivermectin
potenti
antivir
altern
mechan
action
dong
et
al
elfiki
gordon
et
al
li
de
clercq
wang
et
al
would
thu
import
soon
practic
brief
report
rais
possibl
ivermectin
could
use
antivir
limit
similar
fashion
alreadi
report
dong
et
al
elfiki
gordon
et
al
li
de
clercq
wang
et
al
one
proven
benefici
clinic
set
pursu
rapidli
possibl
ivermectin
establish
safeti
profil
human
use
gonzalez
canga
et
al
jan
et
al
buonfrat
et
al
fdaapprov
number
parasit
infect
gonzalez
canga
et
al
buonfrat
et
al
importantli
recent
review
metaanalysi
indic
high
dose
ivermectin
compar
safeti
standard
lowdos
treatment
although
enough
evid
make
conclus
safeti
profil
pregnanc
navarro
et
al
nicola
et
al
critic
next
step
evalu
possibl
benefit
patient
examin
multipl
addit
dose
regimen
mimic
current
approv
usag
ivermectin
human
note
ivermectin
focu
recent
phase
iii
clinic
trial
dengu
patient
thailand
singl
daili
dose
found
safe
produc
clinic
benefit
howev
investig
note
improv
dose
regimen
might
develop
base
pharmacokinet
data
yamasmith
et
al
although
denv
clearli
differ
trial
design
inform
futur
work
go
forward
altogeth
current
report
combin
knownsafeti
profil
demonstr
ivermectin
worthi
consider
possibl
antivir
verohslam
cell
ono
et
al
maintain
earl
minimum
essenti
medium
emem
contain
fetal
bovin
serum
fb
bovogen
biolog
keilor
east
au
mm
lglutamin
mm
sodium
pyruv
mgl
sodium
bicarbon
mm
hepe
mgml
geneticin
co
cell
seed
tissu
cultur
plate
h
prior
infect
isol
moi
infect
media
per
mainten
media
contain
fb
h
media
contain
inoculum
remov
replac
ml
fresh
media
fb
contain
ivermectin
indic
concentr
dmso
alon
incub
indic
day
appropri
timepoint
cell
supernat
collect
spun
min
g
remov
debri
supernat
transfer
fresh
collect
tube
cell
monolay
collect
scrape
resuspens
ml
fresh
media
fb
toxic
control
set
parallel
everi
experi
uninfect
cell
rna
extract
aliquot
sampl
supernat
cell
suspens
use
qiaamp
viru
qiacub
ht
kit
qiagen
hilden
germani
elut
revers
transcript
perform
use
biolin
sensifast
cdna
kit
biolin
london
unit
kingdom
total
reaction
mixtur
contain
rna
extract
transamp
buffer
revers
transcriptas
nucleas
free
water
reaction
incub
min
min
min
triplic
realtim
pcr
analysi
perform
cell
associ
viru
ce
supernat
df
use
probe
either
e
cd
rdrp
ef
gene
result
repres
mean
sd
n
paramet
dose
respons
curv
fit
use
graphpad
prism
determin
ic
valu
indic
g
schemat
ivermectin
propos
antivir
action
coronaviru
bind
coronaviru
cargo
protein
cytoplasm
top
transloc
nuclear
pore
complex
npc
nucleu
complex
fall
apart
viral
cargo
reduc
host
cell
antivir
respons
lead
enhanc
infect
ivermectin
bind
destabilis
heterodim
therebi
prevent
bind
viral
protein
bottom
prevent
enter
nucleu
like
result
reduc
inhibit
antivir
respons
lead
normal
effici
antivir
respons
tta
ata
gtt
aat
agc
gt
revers
ttg
cag
cag
tac
gca
cac
primer
probe
cta
gcc
atc
ctt
act
gcg
ctt
target
betacov
egen
corman
et
al
realtim
rtpcr
assay
perform
appli
biosystem
abi
fast
realtim
pcr
machin
appli
biosystem
foster
citi
ca
usa
use
cycl
condit
min
cdna
use
posit
control
calcul
ct
valu
convert
foldreduct
treat
sampl
compar
control
use
method
fold
chang
viral
rna
express
dmso
alon
sampl
valu
fit
use
paramet
dose
respons
curv
graphpad
prism
work
support
nation
breast
cancer
foundat
fellowship
australia
kmw
nation
health
medic
research
council
nhmrc
australia
senior
prinicpl
research
fellow
sprf
daj
